8-K
filed December 15, 2025, 6:59 PM ET
ticker AEON
CIK 0001837607
other material
confidence high
sentiment positive
materiality 0.78
AEON Biopharma signs definitive exchange with Daewoong; $15M notes swapped for equity, new $1.5M note due 2030
AEON Biopharma, Inc.
- Exchange eliminates >90% of AEON's outstanding debt; Daewoong receives ~23.1M shares, $1.5M new convertible note at 15.79% due Apr 2030.
- Daewoong gets cash-exercise warrant for 8M shares at $1.09392/share, representing up to $8M+ potential proceeds for AEON.
- Exchange remains subject to stockholder vote; closing expected after vote on Jan 21, 2026.
- Daewoong will nominate Seongsoo Park as Class III director at 2026 annual meeting; Park currently on board.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
AEON Biopharma, Inc. issued pre-funded warrants of warrant to Daewoong Pharmaceuticals, Co., LTD for in lieu of Common Stock shares exceeding 49.99% beneficial ownership.
- Security
- warrant
- Shares
- pre-funded warrants
- Purchaser
- Daewoong Pharmaceuticals, Co., LTD
- Consideration
- in lieu of Common Stock shares exceeding 49.99% beneficial ownership
Exact text from the filing
pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) in lieu of any shares of Common Stock that would result in Daewoong’s beneficial ownership of Common Stock exceeding 49.99%
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
AEON Biopharma, Inc. issued up to 8,000,000 shares of warrant to Daewoong Pharmaceuticals, Co., LTD for exercise price of $1.09392 per share.
- Security
- warrant
- Shares
- up to 8,000,000 shares
- Purchaser
- Daewoong Pharmaceuticals, Co., LTD
- Consideration
- exercise price of $1.09392 per share
Exact text from the filing
warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share (the “Common Stock Warrant”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
AEON Biopharma, Inc. issued approximately 23.1 million of common stock to Daewoong Pharmaceuticals, Co., LTD for exchange of Convertible Notes.
- Security
- common stock
- Shares
- approximately 23.1 million
- Purchaser
- Daewoong Pharmaceuticals, Co., LTD
- Consideration
- exchange of Convertible Notes
Exact text from the filing
On December 15, 2025, the Company and AEON Biopharma Sub, Inc., a Delaware corporation (the “AEON Sub”) entered into an Exchange Agreement (the “Exchange Agreement”) with Daewoong consistent with the terms of the Term Sheet pursuant to which the Convertible Notes held by Daewoong would be exchanged for (i) newly issued shares of Common Stock of the Company
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
AEON Biopharma, Inc. issued $1,500,000 of convertible note to Daewoong Pharmaceuticals, Co., LTD for exchange of existing Convertible Notes.
- Security
- convertible note
- Shares
- $1,500,000
- Purchaser
- Daewoong Pharmaceuticals, Co., LTD
- Consideration
- exchange of existing Convertible Notes
Exact text from the filing
a new senior secured convertible note for $1,500,000 (the “New Convertible Note”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
AEON Biopharma, Inc. entered into Exchange Agreement with Daewoong Pharmaceuticals, Co., LTD (effective 2025-12-15).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Daewoong Pharmaceuticals, Co., LTD
- Effective
- 2025-12-15
Exact text from the filing
On December 15, 2025, the Company and AEON Biopharma Sub, Inc., a Delaware corporation (the “AEON Sub”) entered into an Exchange Agreement (the “Exchange Agreement”) with Daewoong consistent with the terms of the Term Sheet pursuant to which the Convertible Notes held by Daewoong would be exchanged for (i) newly issued shares of Common Stock of the Company
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.